Ignite Creation Date:
2025-12-24 @ 11:20 PM
Ignite Modification Date:
2026-01-03 @ 5:56 AM
Study NCT ID:
NCT06545656
Status:
COMPLETED
Last Update Posted:
2025-06-27
First Post:
2024-08-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
Sponsor:
Emory University
Organization:
Study Overview
Official Title:
Daily Doxy: Study of Persons Receiving Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
Status:
COMPLETED
Status Verified Date:
2025-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this project is to collect data regarding the concentrations of doxycycline in mucosal tissues after daily dosing for 7 days in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB) to inform future studies of doxycycline to protect against bacterial sexually transmitted infections (STIs).
Detailed Description:
Recent studies have demonstrated the potential utility of single-dose oral doxycycline postexposure prophylaxis (Doxy-PEP) against bacterial sexually transmitted infections (STIs). Additional dosing strategies are being explored that would also provide protection from bacterial STIs. However, the pharmacokinetics of daily doxycycline and specifically the effect of this dosing on effective drug levels in mucosal tissues is underexplored. A previous pilot study conducted by the Division of human immunodeficiency virus (HIV) Prevention (DHP) Laboratory Branch at the Centers for Disease Control and Prevention (CDC) examined the ability of a single 100mg oral dose of doxycycline to penetrate the vaginal and rectal mucosa. However, data regarding daily doxycycline doses and accumulation of doxycycline with multiple doses are lacking.
The purpose of this project is to collect data regarding the ability of daily oral doxycycline taken for 7 days to concentrate in mucosal tissues in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB). Results from this study will be compared to results of the previous pilot studies conducted by the DHP Laboratory Branch at CDC.
Healthy people assigned male or female sex at birth will take the first dose of doxycycline during the enrollment visit (Hour -144/Day -6) then will take the next 5 doses at home, one per day for the next 5 days. After 6 consecutive days of dosing, study participants will have samples collected (Hour 0/Day 0) and then will take the final dose. Rectal and vaginal swab samples will be obtained 2 to 4 hours after the final dose of doxycycline. Rectal and vaginal biopsy tissue will be collected 24 hours after the last dose.
The purpose of this project is to collect data regarding the ability of daily oral doxycycline taken for 7 days to concentrate in mucosal tissues in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB). Results from this study will be compared to results of the previous pilot studies conducted by the DHP Laboratory Branch at CDC.
Healthy people assigned male or female sex at birth will take the first dose of doxycycline during the enrollment visit (Hour -144/Day -6) then will take the next 5 doses at home, one per day for the next 5 days. After 6 consecutive days of dosing, study participants will have samples collected (Hour 0/Day 0) and then will take the final dose. Rectal and vaginal swab samples will be obtained 2 to 4 hours after the final dose of doxycycline. Rectal and vaginal biopsy tissue will be collected 24 hours after the last dose.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| CDC-STUDY00007429 | OTHER | Centers for Disease Control and Prevention | View |